Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal discomfort, Fatigue, Hypersensitivity, Myalgia, Nasopharyngitis
Clinical narrative: Hives/urticaria; Stomach issue; Itching/pruritus; skin rashes all ove/ rash comes and goes/ worse on his feet/ on his face/ body rash on his trunk and arms; Hypersensitivity reaction; muscle aches/still achy; in general fatigue; fever; cold; This spontaneous case was reported by a consumer and describes the occurrence of NASOPHARYNGITIS (cold), URTICARIA (Hives/urticaria), ABDOMINAL DISCOMFORT (Stomach issue), PRURITUS (Itching/pruritus) and RASH (skin rashes all ove/ rash comes and goes/ worse on his feet/ on his face/ body rash on his trunk and arms) in a 22-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Skin reaction (History of skin reactions (hives, etc.)).   On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 05-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In November 2021, the patient experienced NASOPHARYNGITIS (cold), PRURITUS (Itching/pruritus), RASH (skin rashes all ove/ rash comes and goes/ worse on his feet/ on his face/ body rash on his trunk and arms), HYPERSENSITIVITY (Hypersensitivity reaction), MYALGIA (muscle aches/still achy), FATIGUE (in general fatigue) and PYREXIA (fever). On an unknown date, the patient experienced URTICARIA (Hives/urticaria) and ABDOMINAL DISCOMFORT (Stomach issue). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at a dose of 25 milligram; PARACETAMOL (TYLENOL [PARACETAMOL]) for Adverse event, at a dose of 1 dosage form and IBUPROFEN (ADVIL [IBUPROFEN]) for Adverse event, at a dose of 1 dosage form. At the time of the report, NASOPHARYNGITIS (cold), URTICARIA (Hives/urticaria), ABDOMINAL DISCOMFORT (Stomach issue), PRURITUS (Itching/pruritus), HYPERSENSITIVITY (Hypersensitivity reaction), FATIGUE (in general fatigue) and PYREXIA (fever) outcome was unknown and RASH (skin rashes all ove/ rash comes and goes/ worse on his feet/ on his face/ body rash on his trunk and arms) and MYALGIA (muscle aches/still achy) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-Nov-2021, SARS-CoV-2 test: negative (Negative) Negative.         CC: This is a spontaneous case concerning a 22-year-old male patient with previous history of skin reactions, who experienced the non-serious  expected events skin rash, hypersensitive reaction, myalgia and pyrexia. The benefit-risk relationship of mRNA-1273 is not affected by this report. No concomitant medication was provided by the reporter. The patient had delayed reaction to booster doses started 10 days after vaccination. The patient induced fever, extreme fatigue and muscle ache 2-3 days.  Patient had strep and mono test on 18-Nov-2021, but they were negative. He has a body rash on his trunk and arms. The patient was prescribed steroid that he took for a couple of days, but it was causing him stomach issues. The patient used antihistamine (unspecified) for marginal relief for 6-7 days. The rash had improved not resolved.   This case was linked to MOD-2021-399652 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 20-Nov-2021: Follow up received on 20-NOV-2021 contains no new information On 20-Nov-2021: Follow up information received on 20 Nov 2021 contains event pertaining to first dose and medical history On 28-Nov-2021: Follow up received: Events were added.; Sender's Comments: This is a spontaneous case concerning a 22-year-old male patient with previous history of skin reactions, who experienced the non-serious  expected events skin rash, hypersensitive reaction, myalgia and pyrexia. The benefit-risk relationship of mRNA-1273 is not affected by this report.